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Abstract
Context—In populations of older adults, prediction of coronary heart disease (CHD) events
through traditional risk factors is less accurate than in middle-aged adults. Electrocardiographic
(ECG) abnormalities are common in older adults and might be of value for CHD prediction.
Objective—To determine whether baseline ECG abnormalities or development of new and
persistent ECG abnormalities are associated with increased CHD events.
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Design, Setting, and Participants—A population-based study of 2192 white and black older
adults aged 70 to 79 years from the Health, Aging, and Body Composition Study (Health ABC
Study) without known cardiovascular disease. Adjudicated CHD events were collected over 8
years between 1997–1998 and 2006–2007. Baseline and 4-year ECG abnormalities were classified
according to the Minnesota Code as major and minor. Using Cox proportional hazards regression
models, the addition of ECG abnormalities to traditional risk factors were examined to predict
CHD events.
Main Outcome Measure—Adjudicated CHD events (acute myocardial infarction [MI], CHD
death, and hospitalization for angina or coronary revascularization).
Results—At baseline, 276 participants (13%) had minor and 506 (23%) had major ECG
abnormalities. During follow-up, 351 participants had CHD events (96 CHD deaths, 101 acute
MIs, and 154 hospitalizations for angina or coronary revascularizations). Both baseline minor and
major ECG abnormalities were associated with an increased risk of CHD after adjustment for
traditional risk factors (17.2 per 1000 person-years among those with no abnormalities; 29.3 per
1000 person-years; hazard ratio [HR], 1.35; 95% CI, 1.02–1.81; for minor abnormalities; and 31.6
per 1000 person-years; HR, 1.51; 95% CI, 1.20–1.90; for major abnormalities). When ECG
abnormalities were added to a model containing traditional risk factors alone, 13.6% of
intermediate-risk participants with both major and minor ECG abnormalities were correctly
reclassified (overall net reclassification improvement [NRI], 7.4%; 95% CI, 3.1%–19.0%;
integrated discrimination improvement, 0.99%; 95% CI, 0.32%–2.15%). After 4 years, 208
participants had new and 416 had persistent abnormalities. Both new and persistent ECG
abnormalities were associated with an increased risk of subsequent CHD events (HR, 2.01; 95%
CI, 1.33–3.02; and HR, 1.66; 95% CI, 1.18–2.34; respectively). When added to the Framingham
Risk Score, the NRI was not significant (5.7%; 95% CI, −0.4% to 11.8%).
Conclusions—Major and minor ECG abnormalities among older adults were associated with an
increased risk of CHD events. Depending on the model, adding ECG abnormalities was associated
with improved risk prediction beyond traditional risk factors.
IN POPULATIONS OF OLDER ADULTS, prediction of coronary heart disease (CHD) through traditional risk
factors is less accurate than among middle-aged adults.1 Resting electrocardiographic (ECG)
abnormalities have been shown to be independently associated with incident CHD and
cardiovascular disease (CVD) events,2–8 and ECG is a good candidate to consider for risk
stratification of asymptomatic participants given its low cost, wide use, and safety.9,10
However, performing routine ECG among asymptomatic adults is not supported by current
evidence.11
Considering the higher prevalence of both CVD and ECG abnormalities in older adults, risk
prediction incorporating ECG might be more useful in this group.2,9 To date, few studies
have examined the improvement of CVD risk prediction using ECG abnormalities in a
population of older adults and none could adequately adjust the analyses for presence of
previous CVD and traditional cardiovascular risk factors (CVRFs).12,13 Moreover, no
studies have examined the effect of ECG on net reclassification of participants, a method of
reporting the prognostic properties of markers of cardiovascular risk.14–16
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Our study goal was to determine whether baseline major and minor ECG abnormalities,
development of new ECG abnormalities, and persistent ECG abnormalities during follow-up
were associated with incident CHD events, independent of traditional CVRFs, in a
population-based study of black and white older adults without preexisting CVD.
METHODS
Study Population
Participants were part of the Health, Aging, and Body Composition Study (Health ABC
Study), a population-based cohort study of 3075 community-dwelling men and women aged
70 to 79 years at study entry in 1997–1998.17 Participants were identified from a random
sample of white and black Medicare-eligible adults living in designated zip code areas
surrounding Pittsburgh, Pennsylvania, and Memphis, Tennessee. Participants identified
themselves as black or white race. Details of the eligibility criteria have been previously
described.17 All participants gave written informed consent and the institutional review
board approved the protocol.
Among the 3075 participants, we excluded 842 who had overt CVD at baseline, defined as a
diagnosis of CHD (angina, prior myocardial infarction [MI], angioplasty of coronary
arteries, or coronary artery graft surgery), stroke or transient ischemic attack, peripheral
arterial revascularization, carotid artery disease, heart failure, or having a pacemaker (based
on algorithms mirroring those of the Cardiovascular Health Study).18 We also excluded 41
participants with missing data for any of the traditional risk factors. The final sample for our
analyses of baseline ECG abnormalities was 2192 participants.
ECG Data
Standard 12-lead ECGs were recorded at baseline and at the year 4 visit in the resting supine
position and using strictly standardized procedures in all clinical centers. Electrocardiograms
were sent electronically to an ECG core laboratory at St Louis University Medical Center, St
Louis, Missouri. Each ECG was reviewed by 2 trained coders and discordant results were
adjudicated by a senior coder. Electrocardiograms were coded according to the Minnesota
Code (MC).19 Independent data entry operators entered data twice in an electronic database
and data were adjudicated by a supervisor. Among a random sample of 5% of baseline
ECGs, κ values for the categorization described were 0.90 for major, 0.71 for minor, and
0.82 for no ECG abnormalities.
Electrocardiographic abnormalities were divided into major and minor abnormalities on the
basis of the MC and according to previous publications.7,8,10 Criteria for major prevalent
ECG abnormalities were any of the following: Q-QS wave abnormalities (MC 1-1 to 1-2-8);
left ventricular hypertrophy (MC 3–1); Wolff-Parkinson-White syndrome (MC 6-4-1 or
6-4-2); complete bundle branch block or intraventricular block (MC 7-1-1, 7-2-1, 7–4, or 7–
8); atrial fibrillation or atrial flutter (MC 8–3); or major ST-T changes (MC 4–1, 4–2, 5–1,
and 5–2). Criteria for minor prevalent ECG abnormalities were minor ST-T changes (MC 4–
3, 4-4, 5–3, and 5–4). Participants with both major and minor abnormalities were classified
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as having major abnormalities. Participants without minor or major ECG abnormalities were
classified as having marginal or no abnormalities and their ECG was considered normal.
At 4 years, we analyzed repeat ECG data among 1670 of the participants who had not had
any CHD events during the first 4 years of follow-up. From the base-line sample of 2192
participants, we excluded 424 participants without ECG data at 4 years and 98 participants
who had had a CHD event during the first 4 years of follow-up. These 522 participants were
more likely to be older, of black race, smokers, have hypertension and less education, be less
physically active, and have an increased creatinine level than the participants included in the
repeat ECG analyses at 4 years. For these analyses, participants were classified according to
the presence of any (major, minor, or both) abnormalities at baseline and follow-up. These
participants were then categorized as abnormalities at baseline only, persistent abnormalities
(both baseline and follow-up), incident abnormalities (follow-up only), and no abnormalities
(neither baseline nor follow-up).
CHD Events
We assessed incident CHD events among participants without preexisting CVD at baseline.
Using algorithms mirroring those of the Cardiovascular Health Study,18 diagnoses and cause
of death were adjudicated until 2006–2007, based on interview, review of all hospital
records, death certificates, and other documents by a panel of clinicians blinded to the
results of ECG data at baseline and 4 years. CHD events were defined as acute MI, coronary
death, hospitalization for angina, or coronary revascularization (angioplasty of coronary
arteries and coronary artery bypass graft surgery).20 We also separately analyzed hard CHD
events, defined as MI and CHD deaths (as defined in current guidelines21) and soft CHD
events, defined as hospitalization for angina and coronary revascularization.
Follow-up time was defined by the time from the baseline visit until the first event date (for
those participants who had an event) or was censored at the last contact date (for those
participants who did not have any event or were lost to follow-up) or the day of death (for
those participants who died of noncardiovascular causes). For the analyses of repeat ECGs
at 4 years, the baseline visit was defined as the date of the repeat ECG at 4 years.
Covariates
Covariates included sociodemographic variables (age, sex, self-reported race, study site,
education) as well as physical and biological parameters, including smoking status (current,
past, or never smokers assessed by questionnaire), body mass index (calculated as weight in
kilograms divided by height in meters squared), and total cholesterol, high-density
lipoprotein cholesterol, and creatinine (all measured by a colorimetric technique on a
Johnson & Johnson Vitros 950 analyzer, New Brunswick, New Jersey). Hypertension was
defined via self-report and use of antihypertensive medications, or measured blood pressure,
with systolic of 140 mm Hg or higher, diastolic of 90 mm Hg or higher, or both. Diabetes
was defined as self-reported diagnosis, using any hypoglycemic medication, or both.20 The
use of lipid-lowering drugs, angiotensin-converting enzyme inhibitors, estrogen therapy, and
aspirin was assessed using Iowa Drug Information System codes.
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Statistical Analyses
Differences in proportions and means of covariates across participants with and without
incident CVD events during follow-up were assessed by use of χ2 and analysis of variance
statistics, respectively. For covariates that were not normally distributed, median values with
interquartile ranges were reported and the use of Mann-Whitney U statistics. We used Cox
proportional hazard regression models to assess the improvement in prediction of future
CHD events by including ECG data.22,23 The level of significance was established a priori
at 2-sided P<.05. Primary analyses were adjusted for traditional risk factors included in the
current Framingham Risk Score (FRS),21 as well as diabetes, a strong independent CHD risk
factor.24 Systolic blood pressure was used as a continuous variable. In sensitivity analyses,
we examined associations in models further adjusted for other potential riskfactors or
confounders (ie, self-reported race, education, site, low-density lipoprotein cholesterol,
creatinine level, alcohol consumption, physical activity, and use of statins, angiotensin-
converting enzyme inhibitors, and estrogen). We further examined the overall
reclassification rate of ECG abnormalities over the FRS categories (without diabetes). We
did not use the FRS in the main analyses, because it has not been validated among adults
aged older than 75 years. We also performed stratified analyses by race (white vs black). We
addressed the potential concern of competing causes of death in this older population in a
competing risk Fine and Gray model.25
To assess model calibration, we used Parzen adaptation of the Hosmer-Lemeshow test to the
Cox proportional hazard regression model.26 We verified the proportional hazards
assumption using graphical methods and Schoenfeld tests. We examined several statistical
measures according to recommendations for the assessment of novel markers.15 To assess
improvements in discrimination, we used Harrell C index,27 an adaptation of the C statistic
or area under the receiver operating characteristic curve to the Cox proportional hazard
regression model. We adjusted the C index for optimism by using 10-fold cross-validation
and obtained confidence intervals using bootstrap resampling with 500 repetitions. Net
reclassification rates were computed as described previously.14,28 To avoid extrapolation
beyond the range of our data, we used Cox proportional hazard regression models to
estimate 7.5-year risks rather than 10-year risks.29 We used 7.5% to 15% risk over 7.5 years
corresponding with the thresholds used in the Third Report of the National Cholesterol
Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) guidelines to define intermediate-risk
categories (10%–20% over 10-year risk).21 We also assessed net reclassification
improvement (NRI) in intermediate-risk categories (10%–20% over 10-year risk), defined as
7.5% to 15% risk for 7.5-year time-frame.30 The NRI is estimated according to the method
by Pencina et al14 defined as {([number of events reclassified higher – number of events
reclassified lower]/number of events) – ([number of non-events reclassified lower – number
of non-events reclassified higher]/number of non-events)}. In addition, we estimated an
alternate reclassification method for the intermediate-risk group (7.5%–15% over 7.5-year
risk), the adjusted clinical NRI,31 which takes into account the observed reclassification
rates for the expected rates under the null hypothesis of no net reclassification. In addition,
we estimated integrated discrimination improvement (IDI),14 defined as the average increase
in predicted risk among cases, plus the analogous average decrease among controls, afforded
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by information on ECG abnormalities. In contrast to both NRI measures, the IDI is
calculated using predicted risks before grouping into categories and is therefore not affected
by choice of cutoff values.14
Statistical analyses were conducted using Stata version 12 (Stata Corporation) and R version
2.14.1 (R Project for Statistical Computing, http://www.r-project.org).
RESULTS
Baseline ECGs
At baseline, mean (SD) age was 73.5 (2.8) years, 55% were women, and 41% were of black
race (Table 1). Of the 2192 participants, 506 (23%) had major and 276 (13%) had minor
ECG abnormalities. During a median follow-up of 8.2 years (range, 9 days-10.2 years), 351
participants had CHD events (96 CHD deaths, 101 acute MIs, and 154 hospitalizations for
angina or coronary revascularizations) and 602 died (96 deaths from CHD).
Major and minor ECG abnormalities at baseline were both associated with an increased risk
of CHD. The Kaplan-Meier estimates of CHD cumulative hazard over time for those
participants without ECG abnormalities vs any (minor and/or major) ECG abnormalities
(Figure 1) and for those participants without ECG abnormalities vs major and minor ECG
abnormalities (Figure 2) were calculated. The CHD rate per 1000 person-years in
participants with no ECG abnormalities was 17.2 (29.3 per 1000 person-years in those with
minor ECG abnormalities and 31.6 per 1000 person-years in those with major ECG
abnormalities at baseline) (Table 2). After adjustment for CVRFs including age, sex, total
and high-density lipoprotein cholesterol, systolic blood pressure, smoking, and diabetes,
hazard ratios (HRs) and 95% CIs for CHD events for participants with minor ECG
abnormalities vs participants without abnormalities was 1.35 (95% CI, 1.02–1.81) and 1.51
(95% CI, 1.20–1.90) for those with major ECG abnormalities at baseline. Results were
similar when further adjusting for race, education, site, low-density lipoprotein cholesterol,
creatinine (as natural logarithm), alcohol consumption, physical activity, statins,
angiotensin-converting enzyme inhibitors, and estrogen use (Table 2).
Stratification of analyses by race showed similar findings between white and black
participants (eTable 1, http://www.jama.com). The HRs adjusted for CVRFs were 1.58
(95% CI, 1.19–2.09) for hard CHD events (absolute risk, 16.1 vs 9.4 per 1000 person-years
among those without ECG abnormalities) and 1.67 (95% CI, 1.21–2.31) for soft events
(absolute risk, 13.6 vs 7.5 per 1000 person-years among those without ECG abnormalities)
(eTable 2). Overall, associations with minor ECG abnormalities were less strong in these
stratified analyses, although associations with major or any ECG abnormalities remained
similar. A Fine and Gray model treating all-cause mortality as a competing risk yielded an
HR of 1.63 (95% CI, 1.32–2.01), which was similar to the HR found for the main model
adjusted for traditional CVRFs.
The addition of ECG abnormalities to the model adjusted for traditional CVRFs resulted in
reclassification of 13.6% of intermediate-risk participants and 7.1% in the overall sample
(Table 3). When ECG abnormality was added to the model adjusted for traditional CVRFs,
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176 intermediate-risk participants (8%) were reclassified as high risk, of whom 27 (15.2%)
experienced events. Conversely, 136 participants (6.2%) were reclassified as low risk, of
whom 7 (5.2%) experienced events. Using the alternate reclassification method, which takes
into account the observed rates vs the expected rates under the null hypothesis, 7.9% of
intermediate-risk participants without events and −1.2% of participants with events were
reclassified into the highest- and lowest-risk categories (adjusted clinical NRI, 6.7%; 95%
CI, 1.2%–19.3%). With this method, the greatest effect of adding ECG abnormalities to the
model was on reclassifying intermediate-risk participants without events into the lowest-risk
category. Including ECG abnormality in the model adjusted for CVRFs placed 65% of the
overall population into either the highest-risk or lowest-risk categories vs 49% with
traditional risk factors alone. With the addition of ECG abnormality to the model, 0.9%
fewer of those who experienced events were reclassified as high risk and an additional 8%
of those who did not experience events were reclassified as low risk (NRI for the overall
sample, 7.4%; 95% CI, 3.1%–19.0%; and IDI, 0.99%; 95% CI, 0.32%–2.15%). When using
the FRS alone, the reclassification rates achieved with additional ECG abnormalities were
lower (NRI, 5.7%; 95% CI, −0.4% to 11.8%; and IDI, 1.03%; 95% CI, 0.56%–1.50%).
In addition to age and sex, the model fit and discrimination (measured by C index) was
greater for ECG abnormalities than for each traditional risk factor for the prediction of CHD
events (eTable 3). Overall, a model with all CVRFs included did not show a good
calibration (goodness of fit P=.03) and was not improved by the addition of ECG
abnormalities (goodness of fit P=.01) (eTable 3).
Follow-up ECGs
Of the 1670 adults with a second ECG after 4 years, 208 had a new abnormality and 416 had
a persistent abnormality. During a median follow-up of 6.4 years (maximum, 7.3 years), 185
participants had CHD events and 348 died (57 from CHD).
After adjustment for CVRFs, both new and persistent ECG abnormalities at 4 years were
associated with an increased risk of subsequent CHD events (for new abnormalities: HR,
2.01; 95% CI, 1.33–3.02; and for persistent abnormalities: HR, 1.66; 95% CI, 1.18–2.34).
The absolute risk was 33.2 per 1000 person-years in those with new and 27.8 per 1000
person-years in those with persistent ECG abnormalities (Table 4). Risk increased from
those with no ECG abnormality and abnormality at baseline only compared with those with
persistent abnormality at 4-year follow-up (P for trend=.01) in multivariate-adjusted models
(Table 4).
The associations between major and minor ECG abnormalities at baseline and all-cause
mortality were not statistically significant (Table 2). The all-cause mortality rate in
participants with no ECG abnormalities was 31.0 per 1000 person-years, in those with minor
ECG abnormalities at baseline was 32.9 per 1000 person-years, and in those with major
ECG abnormalities at baseline was 37.8 per 1000 person-years. After adjustment for
CVRFs, the HRs were 0.95 (95% CI, 0.75–1.22) for minor ECG abnormalities and 1.17
(95% CI, 0.97–1.41) for major ECG abnormalities.
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COMMENT
Our results demonstrate that in a population-based study of elderly men and women without
preexisting CVD, ECG abnormalities were associated with an increased risk of CHD and
significantly improved the prediction of CHD events beyond traditional CVRFs. Addition of
ECG data reclassified 13.6% of the intermediate-risk participants. New and persistent
abnormalities in the ECG performed 4 years later were associated with CHD beyond
CVRFs.
Several previous studies reported an association between ECG abnormalities and CHD
outcomes, but none assessed reclassification and few examined a population of older
adults.10,12,13 In postmenopausal women aged 55 to 79 years, Denes et al10 found that
baseline major and minor as well as incident ECG abnormalities were associated with
significantly increased risks for CHD events, independent of established risk factors and
hormone treatment. Although 20% of the sample (n=2911) were older than 70 years,
complete data on CVRFs was only available in 10% of the participants and reclassification
was not assessed (85% of the participants included were white and 6% were black). The
authors observed an interaction of borderline significance between ECG abnormalities and
race on CVD events, suggesting that white women with an abnormal baseline ECG had a
higher risk for CVD than nonwhite women. In our study, 41% of our sample population was
black. We found the HR associated with ECG abnormalities to be similar in black and white
individuals (eTable 1). Other previous studies of the ability of baseline ECG to predict CVD
mortality did not exclude those individuals with a history of CVD32 or did not measure
CVD.13
When we restricted our sample to the intermediate-risk category, 14% of participants were
reclassified into higher-risk and lower-risk categories. Using a recent method that takes into
account the expected number of participants reclassified, 6.7% (95% CI, 1.2%–19.3%) of
intermediate-risk participants were reclassified, with ECG mainly reclassifying participants
without events into the lowest-risk category. The NRI for ECG in our study was similar or
higher than the NRI for biomarkers in previous studies. We found an NRI of 6.6% in the
Health ABC Study for interleukin 6 (IL-6) and an NRI of 3.3% for ankle brachial index
beyond CVRFs.29 The net risk reclassification with ECG in our population of older adults vs
traditional CVRFs was similar to that reported with C-reactive protein in middle-aged
women (5.7% overall).30 The association between C-reactive protein and CHD events in our
previous publication on this population of older adults was weaker and not statistically
significant after adjusting for additional CVRFs.29 However, even if the NRI of 7.1% was
better than other markers of inflammation, it is much lower than the NRI recently found for
coronary artery calcification score measured with computed tomography.33 Polonsky et al33
found an NRI of 25% for the entire population and an NRI of 55% for individuals at
intermediate risk in a population of 5931 adults aged 45 to 85 years, without known CVD
and diabetes at baseline and followed up for 5 years. No specific NRI were reported for
older adults. Cautious interpretation should be made when comparing the NRI between the 2
studies—reclassification is highly dependent on the cut-points used to define risk categories
and these differed between studies, as did primary outcome definitions and length of follow-
up.34
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What are the implications of our study? The US Preventive Services Task Force
recommends against systematic screening with ECG in asymptomatic populations.11 They
based their recommendations on the lack of clinical trials studying clinical outcomes after
ECG screening and mentioned the low prevalence of ECG abnormalities in younger
populations. In contrast with the low prevalence of ECG in younger populations, 36% of our
studied population had any ECG abnormality at baseline. The ECG screening may be useful
among populations of older adults, but the benefit was small and our results need to be
validated in additional cohorts. The benefits of ECG screening should also be examined in
clinical trials, as recommended by the US Preventive Services Task Force. Among different
noninvasive screening methods studied to date with the NRI, coronary artery calcification
score seems the most promising tool to predict CHD events.33 The intrinsic risk of
computed tomography of induced cancer35,36 might be lower in older adults,36 but the
benefit of reclassification would need to be analyzed in the context of its high costs. The
safety, low cost, and wide availability of ECG are advantages as a screen for subclinical
CVD. An electronic method of reading the ECGs might facilitate the use of ECG data in
clinical practice by permitting direct inclusion of data into an individual risk calculator
alongside other CVRFs of electronic health records.9Further research should compare the
NRI of coronary artery calcification score to a model with traditional risk factors alone and a
model with traditional risk factors and ECG or other novel promising biomarkers.
Our study has several strengths and limitations. The data were drawn from a well-
characterized population-based cohort of older adults and contained a high number of CHD
events during 8 years of follow-up. All CHD events were formally adjudicated.20 However,
CHD events that did not require hospitalization were not tracked and potential associations
between ECG and these more minor CHD events might be lower. Presence of ECG
abnormalities might have led to an increased risk of being hospitalized for suspected angina,
thereby producing a bias toward higher hospitalization rates for angina in participants with
ECG abnormalities at baseline. To evaluate this possibility, we analyzed “hard” CHD
outcomes and still found a positive association.
The association between ECG abnormalities and CHD events also could be confounded by
participants who died without experiencing CHD during follow-up. A sensitivity analysis
treating all-cause mortality as a competing risk showed that all-cause mortality did not
substantially influence our analyses. Our study sample did not permit subgroup analyses to
assess risk of CHD events associated with each specific ECG abnormality. When we used
the traditional CVRFs included in the FRS, the C index was 0.58 (eTable 3), which was
consistent with prior studies in older adults.1,29 When we used the FRS, which has not been
validated in those participants older than 75 years, the additional contribution of the ECG
was not significant. Traditional risk factors have weaker associations with CHD events in
older adults than in younger adults.37 Furthermore, our model with all CVRFs and ECG
abnormalities did not achieve good calibration. For possible development of a future risk
score using ECG abnormalities (not the study goal), a better calibrated model would need to
account for nonlinear responses to the CVRFs, as well as potential interactions between
them.
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We also conducted analyses on repeat ECGs, but 424 participants with no repeat ECG data
at 4 years had significantly different baseline characteristics than participants with repeat
ECG data, leading to a potential selection bias. Therefore, the HRs between the main
analyses at baseline and secondary analyses on repeat ECG data at 4 years should not be
directly compared. Reclassification was not assessed for participants with new abnormalities
on 4-year ECG data, given the limited follow-up thereafter and the low number of
participants with new abnormalities (n=208).
Another consideration is whether our study conditions can be replicated in the clinical
setting. The ECG reading was not automated and each ECG was reviewed by 2 trained
coders; discordant results were adjudicated by a senior coder. Our results are concordant
with studies using different ECG classification and reading methods. For example, Denes et
al10 used the Nova-code, which permits automated ECG reading through a computer, to
code ECGs and found similar associations between minor ECG changes and CHD events.
Considering that previous literature shows large variations in accuracy of ECG reading in
the clinical setting,38 precise estimation of how our results may vary in the clinical setting is
not possible. Reproducibility and reclassification using ECG may be lower in the clinical
setting compared with our results.
In conclusion, we found that major and minor ECG abnormalities are associated with future
CHD events and provide modestly improved risk reclassification beyond traditional risk
factors. Risk prediction with traditional risk factors is less accurate in older persons
compared with middle-aged adults.1 Given the safety, the low cost, and the wide availability
of ECG, ECG data might be useful to improve CHD risk prediction in older adults. Whether
ECG should be incorporated in routine screening of older adults should be evaluated in
randomized controlled trials.
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Figure 1.
Kaplan-Meier Estimates of CHD Cumulative Hazard Over Time of Any vs No ECG Abnormality
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Figure 2.
Kaplan-Meier Estimates of CHD Cumulative Hazard Over Time of Major and Minor vs No ECG Abnormality
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Table 1
Baseline Characteristics of the Study Populationa
No. (%) of Participants
Characteristics All (N = 2192) No ECG Abnormality(n = 1410)
Minor ECG
Abnormality (n =
276)
Major ECG
Abnormality (n =
506)
P Value
Age, mean (SD), y 73.5 (2.8) 73.4 (2.8) 73.5 (2.7) 73.8 (3.0) .01
Women 1211 (55.3) 796 (56.5) 153 (55.4) 262 (51.8) .19
White race 1292 (58.9) 896 (63.6) 139 (50.4) 257 (50.8) <.001
Site
 Memphis, TN 1125 (51.3) 704 (49.9) 148 (53.6) 273 (53.9)
.21
 Pittsburgh, PA 1067 (48.7) 706 (50.7) 128 (46.4) 233 (46.1)
Education
 <High school 532 (24.3) 299 (21.2) 79 (28.6) 154 (30.4)
<.001 High school graduate 733 (33.5) 491 (34.8) 86 (31.2) 156 (30.8)
 Postsecondary 922 (42.2) 617 (43.8) 111 (40.2) 194 (38.3)
Smoking status
 Never 1015 (46.3) 662 (46.9) 120 (43.5) 233 (46.0)
.36 Current 221 (10.1) 145 (10.3) 34 (12.3) 42 (8.3)
 Former 956 (43.6) 603 (42.8) 122 (44.2) 231 (45.7)
Alcohol, drinks/wk
 <1 1534 (70.3) 969 (69.0) 195 (71.2) 370 (73.4)
.46 1–7 482 (22.1) 317 (22.6) 60 (21.9) 105 (20.8)
 >7 166 (7.6) 118 (8.4) 19 (6.9) 29 (5.8)
Physical activity, kcal/wk
 <500 1147 (52.3) 697 (49.4) 163 (59.1) 287 (56.7)
.007 500–1499 598 (27.3) 409 (29.0) 67 (24.3) 122 (24.1)
 ≥1500 447 (20.4) 304 (21.6) 46 (16.7) 97 (19.2)
Hypertension 1257 (57.3) 748 (53.0) 165 (59.8) 344 (68.0) <.001
Diabetes mellitus 292 (13.3) 162 (11.5) 50 (18.2) 80 (15.8) .002
BMI, mean (SD) 27.4 (4.9) 27.0 (4.7) 28.6 (5.4) 27.9 (5.0) <.001
Systolic BP, mean (SD) 136 (21) 133 (20) 136 (19) 142 (23) <.001
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No. (%) of Participants
Characteristics All (N = 2192) No ECG Abnormality(n = 1410)
Minor ECG
Abnormality (n =
276)
Major ECG
Abnormality (n =
506)
P Value
Diastolic BP, mean (SD) 72 (12) 71 (11) 72 (12) 73 (13) <.001
Cholesterol, mean (SD), mg/dL
 Total 205 (38) 206 (39) 203 (37) 204 (37) .51
 HDL 55 (17) 56 (17) 54 (16) 55 (17) .09
 LDL 123 (34) 123 (35) 122 (35) 122 (33) .81
Triglycerides, median (IQR) 116 (87–160) 116 (87–159) 120 (87–167) 115 (85–159) .41
Creatinine, median (IQR), mg/dL 1.0 (0.9–1.1) 1.0 (0.8–1.1) 1.0 (0.9–1.2) 1 (0.9–1.2) <.001
FRS, mean (SD), %b 12.6 (7.3) 12 (7.2) 13.2 (7.4) 13.9 (7.2) <.001
Categories of FRS, %
 <5.0 297 (13.6) 220 (15.6) 34 (12.3) 43 (8.5)
<.001
 5.0–9.9 525 (23.9) 353 (25.0) 62 (22.5) 110 (21.7)
 10.0–19.9 853 (38.9) 535 (38.0) 106 (38.4) 212 (41.9)
 ≥20.0 517 (23.6) 302 (21.4) 74 (26.8) 141 (27.9)
Medication use
 Lipid-lowering 228 (10.4) 138 (9.8) 39 (14.1) 51 (10.1) .09
 ACE inhibitors 272 (12.4) 158 (11.2) 37 (13.4) 77 (15.2) .06
 Hormone therapy in women 285 (23.5) 213 (26.8) 31 (20.3) 41 (15.7) <.001
 Aspirin 411 (18.8) 257 (18.2) 50 (18.1) 104 (20.6) .50
Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass index, calculated as weight in kilograms divided by height in meters
squared; BP, blood pressure; ECG, electrocardiographic; FRS, Framingham Risk Score; HDL, high-density lipoprotein; IQR, interquartile range;
LDL, low-density lipoprotein.
SI conversions: To convert total, HDL, and LDL cholesterol to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply by 0.0113; and
creatinine to μmol/L, multiply by 88.4.
aSee “Methods” section for definitions of hypertension and minor and major ECG abnormalities. Statistical analysis was by analysis of variance or
χ2 test. Systolic BP was used as a continuous variable. Mann-Whitney rank sum test was performed for triglycerides. Creatinine was used on log-
transformed values.
b
Estimation of 10-year risk of coronary heart disease with information about age, sex, smoking status, total cholesterol, HDL cholesterol, and
BP.21
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Table 2
Incidence Rates and HRs for CHD Events and All-Cause Mortality in Older Adults According to ECG
Abnormalities
No ECG
Abnormality (n =
1410)
Minor ECG
Abnormality (n =
276)
Major ECG
Abnormality (n =
506)
Any ECG
Abnormality (n =
782)
CHD events (n = 351)a
 Rate per 1000 person-years (95%
CI) 17.2 (14.8–19.8) 29.3 (22.2–38.0) 31.6 (26.0–38.0) 30.8 (26.3–35.8)
 CVRFs, adjusted HR (95% CI)b 1.00 1.35 (1.02–1.81) 1.51 (1.20–1.90) 1.64 (1.32–2.03)
 Multivariate-adjusted HR (95% CI)c 1.00 1.39 (1.04–1.85) 1.47 (1.16–1.86) 1.63 (1.31–2.02)
All-cause mortality (n = 602)
 Rate per 1000 person-years (95%
CI) 31.0 (27.9–34.3) 32.9 (25.9–41.3) 37.8 (32.1–44.2) 36.1 (31.1–41.0)
 CVRFs, adjusted HR (95% CI)b 1.00 0.95 (0.75–1.22) 1.17 (0.97–1.41) 1.11 (0.94–1.31)
 Multivariate-adjusted HR (95% CI)c 1.00 0.97 (0.76–1.24) 1.09 (0.90–1.31) 1.06 (0.89–1.25)
Abbreviations: CHD, coronary heart disease; CVRFs, cardiovascular risk factors; ECG, electrocardiographic; HRs, hazard ratios.
a
Includes acute myocardial infarction, coronary death, hospitalization for angina, angioplasty of coronary arteries, and coronary artery bypass graft
surgery.
bAdjusted for age, sex, total and high-density lipoprotein cholesterol, systolic blood pressure, smoking, and diabetes.
cAdjusted for CVRFs (including age, sex, total and high-density lipoprotein cholesterol, systolic blood pressure, smoking, and diabetes) and race,
education, site, low-density lipoprotein (LDL) cholesterol, creatinine (as natural logarithm), alcohol consumption, physical activity, statins,
angiotensin-converting enzyme inhibitors, and estrogen use. A total of 2168 participants analyzed (23 participants with missing data for LDL
cholesterol, 10 for alcohol consumption, 5 for education, and 1 for creatinine, resulting in 24 participants with 1 or more missing values excluded
from the multivariate analysis).
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Table 3
Predicted Risk of CHD Events Using a Multivariate Risk Prediction Model With and Without Inclusion of
ECG Dataa
Model With ECG
Model Without EGC
Frequency, %
Rate Reclassified, %b<7.5 7.5–<15.0 ≥15.0 Total
Participants who experience a CHD event, %
<7.5 4 2 0 6
7.5–<15.0 7 91 27 125
≥15.0 0 25 195 220
Total 11 118 222 351 −0.9
Participants who do not experience a CHD event, %
<7.5 74 17 0 91
7.5–<15.0 129 678 149 956
≥15.0 0 189 605 794
Total 203 884 754 1841 8.3
Abbreviations: CHD, coronary heart disease; ECG, electrocardiographic.
aNet reclassification improvement (sum of the percentages of correctly reclassified participants with and without CHD events): 7.4%; 95% CI,
3.1%–19.0%. Identification discrimination improvement: 0.99%; 95% CI, 0.32%–2.15%.
b
Proportion of all participants who were “correctly” reclassified minus the proportion of each group reclassified in the “wrong” direction.
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Table 4
Hazard Ratios (HRs) for Incidence of CHD Events in Older Adults According to the Presence of Any ECG
Abnormality at Baseline and Any Incident and Persistent ECG Abnormalities at Follow-upa
No ECG
Abnormality (n =
902)
Abnormality at
Baseline Only (n =
144)
Persistent
Abnormality at 4-
Year Follow-up (n =
416)
New Abnormality at
4-Year Follow-up (n
= 208) P Value
b
CHD events (n = 185)c
 No. of events 77 18 57 33
 Rate per 1000 person-years
(95% CI) 16.5 (12.3–20.6) 24.9 (14.7–39.2) 27.8 (21.0–36.0) 33.2 (22.8–46.6)
 Age-adjusted HR (95% CI) 1.00 1.51 (0.90–2.52) 1.66 (1.18–2.34) 2.01 (1.33–3.02) .003
 CVRFs, adjusted HR (95%
CI)d 1.00 1.43 (0.85–2.39) 1.52 (1.07–2.16) 1.97 (1.31–2.96) .01
All-cause mortality (n = 348)
 No. of events 172 22 100 54
 Rate per 1000 person-years
(95% CI) 32.2 (27.6–37.4) 25.8 (16.2–39.0) 41.4 (33.7–50.3) 45.9 (34.4–59.9)
 Age-adjusted HR (95% CI) 1.00 0.83 (0.53–1.29) 1.25 (0.98–1.61) 1.45 (1.07–1.97) .01
 CVRFs, adjusted HR (95%
CI)d 1.00 0.77 (0.49–1.20) 1.19 (0.92–1.53) 1.40 (1.03–1.91) .02
Abbreviations: CHD, coronary heart disease; CVRFs, cardiovascular risk factors; ECG, electrocardiographic.
aAny ECG abnormality indicates major and/or minor ECG abnormality. Inclusion of 1670 participants without events during first 4 years of
follow-up and ECG data at baseline and 4-year follow-up only.
b
P value for linear trend across no abnormality, abnormality at baseline, and persistent abnormality at follow-up.
c
Includes acute myocardial infarction, coronary death, hospitalization for angina, angioplasty of coronary arteries, and coronary artery bypass graft
surgery.
dAdjusted for age, sex, total and high-density lipoprotein cholesterol, systolic blood pressure, smoking, and diabetes.
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